Newbury Pharmaceuticals AB (OSTO:NEWBRY) ROCE % : -29.21% (As of Feb. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Newbury Pharmaceuticals AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Newbury Pharmaceuticals AB's annualized ROCE % for the quarter that ended in Feb. 2024 was -29.21%.

Newbury Pharmaceuticals AB ROCE % Historical Data

The historical data trend for Newbury Pharmaceuticals AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Newbury Pharmaceuticals AB ROCE % Chart

Newbury Pharmaceuticals AB Annual Data

Trend

Aug21

Aug22

Aug23

ROCE %

-14.35

-24.59

-27.37

Newbury Pharmaceuticals AB Quarterly Data
	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
ROCE %	Get a 7-Day Free Trial									-26.57	-24.24	-28.89	-18.50	-29.21

Newbury Pharmaceuticals AB ROCE % Calculation

Newbury Pharmaceuticals AB's annualized ROCE % for the fiscal year that ended in Aug. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Aug. 2023 )		(A: Aug. 2022 )		(A: Aug. 2023 )
	=	-19.431	/	( ( (86.905 - 6.059)	+	(72.918 - 11.769) )	/ 2 )
	=	-19.431	/	( (80.846	+	61.149)	/ 2 )
	=	-19.431	/	70.9975
	=	-27.37 %

Newbury Pharmaceuticals AB's ROCE % of for the quarter that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2024 )		(Q: Nov. 2023 )		(Q: Feb. 2024 )
	=	-18.332	/	( ( (94.09 - 21.272)	+	(84.126 - 31.417) )	/ 2 )
	=	-18.332	/	( ( 72.818	+	52.709 )	/ 2 )
	=	-18.332	/	62.7635
	=	-29.21 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2024) EBIT data.

Newbury Pharmaceuticals AB (OSTO:NEWBRY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Newbury Pharmaceuticals AB ROCE % Related Terms

Thank you for viewing the detailed overview of Newbury Pharmaceuticals AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Newbury Pharmaceuticals AB (OSTO:NEWBRY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Newbury Pharmaceuticals AB (OSTO:NEWBRY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.newburypharma.com

Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.

Newbury Pharmaceuticals AB (OSTO:NEWBRY) Headlines

No Headlines